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Introduction
Drug-resistant strains of many bacteria have been reported.
Trends in drug resistance of major bacterial strains isolated
from clinical materials will be outlined below, citing our
own data as well.
Bacteroides fragilis group
Bacteria referred to collectively as the ‘‘Bacteroides fra-
gilis group (B. fragilis group)’’ are predominant among the
anaerobes isolated from clinical materials. Diverse drug-
resistant strains have been reported for these bacteria. Most
strains of the B. fragilis group isolated from clinical cases
produce b-lactamase. Originally, the b-lactamase produced
by the B. fragilis group often extended the spectrum type
and manifested diverse resistance to b-lactams such as
penicillins and cephems. These strains often show resis-
tance to multiple drugs such as tetracycline (TC), macro-
lides and ﬂuoroquinolones, in addition to b-lactams.
Resistance to clindamycin (CLDM) is seen in 30–40% of
the B. fragilis group. Bacteria of genus Bacteroides other
than B. fragilis, i.e. non-B. fragilis microorganisms such as
B. thetaiotaomicron, tend to show broader drug resistance
than B. fragilis. From the viewpoint of drug resistance, the
B. fragilis group should be divided into B. fragilis and non-
B. fragilis. Except for the occasionally seen highly resistant
strains, B. fragilis is susceptible to cephamycins, while
non-B. fragilis is resistant to cephamycins. Drugs which are
expected to exert activity against this group of bacteria, and
hence should be selected before attempts at empiric ther-
apy, are carbapenems, b-lactams with b-lactamase inhibi-
tor, and some of the new ﬂuoroquinolones planned for
clinical introduction in the near future. In cases in which
the isolated bacterium has been identiﬁed as B. fragilis,
cephamycins are also expected to be effective. The drug
most reliable for such cases is metronidazole, although this
drug is not marketed for this purpose in Japan.
It needs to be borne in mind that some strains of the
B. fragilis group show resistance to these drugs, usually
expected to show efﬁcacy against this group, although the
frequency of isolation of such resistant strains is low.
Particular care is needed of carbapenem-resistant strains.
Carbapenem-resistant strains, which exert resistance via
metallo-b-lactamase, are highly resistant not only to
carbapenems in general but also to b-lactams with a
b-lactamase inhibitor, and other all b-lactams (including
cephamycin), although such strains have been detected
only among the B. fragilis. It is not uncommon for these
strains to also show resistance to CLDM and TC. In any
event, it is essential to seek drugs to which these strains are
susceptible among drugs of this and other families. Mod-
erate resistance to carbapenems is seen among some strains
of both B. fragilis and non-B. fragilis. These strains are
likely to show resistance to b-lactams in general, but some
B. fragilis strains are susceptible to cephamycin.
Genus Prevotella
b-Lactamase-producing bacteria of genus Prevotella tend
to show resistance to b-lactams, similar to the resistance
exhibited by B. fragilis. In fact, the percentage of b-lac-
tamase-producing strains is close to 90% for non-pig-
mented Prevotella, such as P. bivia. These strains show
resistance to many b-lactams, excluding cephamycin,
b-lactams with b-lactamase inhibitors, and carbapenems.
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The MIC of the drugs, to which these strains show resis-
tance, is high for all of these strains. Among the black-
pigmented bacteria of genus Prevotella such as P. inter-
media, about 60% now produce b-lactamase, although very
few of these bacteria produced b-lactamase in the past.
Although the resistance of bacteria of genus Prevotella is
not as high as that of B. fragilis, the MIC of b-lactams
(penicillins, cephams, etc.) against these b-lactamase-pro-
ducing strains of Prevotella is markedly higher than that
against non-b-lactamase-producing strains. Moderate or
higher resistance is exhibited by these strains. Resistance to
carbapenems has been reported for P. nigrescens, P. in-
termedia, P. melaninogenica and P. oralis isolated from
dental patients [1]. Regarding resistance of Prevotella to
other drugs, it is known that 15–30% of Prevotella strains
show resistance to ﬂuoroquinolones (developed many years
ago and since used frequently) and about 40% show
resistance to TC. Resistance to CLDM is seen in about 10%
of all Prevotella strains.
Genus Fusobacterium
Bacteria of genus Fusobacetrium often isolated from
clinical materials are F. nucleatum, F. varium and
F. mortiferum. All three of these bacteria are resistant to
macrolides. Like B. fragilis, F. varium and F. mortiferum
show resistance to various antibacterial agents. At present,
however, these bacteria are mostly susceptible to CLDM.
F. nucleatum does not show extensive resistance,
unlike F. varium and F. mortiferum, but not a few strains of
F. nucleatum show high resistance to certain penicillins.
Bilophila wadsworthia, Sutterella wadsworthensis
and genus Desulfovibrio
All of these bacteria grow slowly and form small colonies.
They tend to be overlooked if samples are cultured with
non-selective medium alone. These bacteria show resis-
tance to certain drugs, including those used for the treat-
ment of anaerobic infections.
B. wadsworthia began to attract clinical attention rela-
tively recently. Its isolation from cases with intraperitoneal
infections and various other infections has been reported.
This bacterium produces b-lactamase and shows resistance
to b-lactams (particularly penicillins). The resistance of
this bacterium to drugs is affected by the bacterial density
in individual cases. This bacterium tends to also be resis-
tant to macrolides. S. wadsworthensis, also isolated from
intraperitoneal infection cases, does not grow in carbon
dioxide culture but grows well in microaerophilic envi-
ronments. This bacterium is resistant to metronidazole [2].
Bacteria of genus Desulfovibrio are reportedly resistant to
some penicillins and cephems [3].
Genus Clostridium
C. perfringens shows resistance only to a small number of
drugs, but some strains of this bacterium are resistant to TC
and CLDM. Bacteria of genus Clostridium other than
C. perfringens occasionally show resistance to macrolides,
TCs, CLDM and cephems. It is well known that C. difﬁcile,
responsible for antibacterial drug-associated diarrhea, is
highly resistant to multiple drugs. Other bacteria of genus
Clostridium which are often isolated from clinical materi-
als and require caution because of drug resistance are
C. ramosum, C. innocum and the C. clostridioforme group
(C. clostridioforme, C. bolteae, C. hathewayi, etc.).
Anaerobic gram-positive cocci
Until recently, Peptostreptococcus anaerobius (one of the
anaerobic gram-positive cocci isolated at a high frequency)
and three other bacteria (Finegoldia magna, Parvimonas
micra and Peptoniphilus asaccharolyticus) were regarded
as belonging to the same genus (Peptostreptococcus). For
this reason, the susceptibilities of these four bacteria tend
to be discussed collectively in the context of the suscepti-
bility of genus Peptostreptococcus. In practice, however,
drug susceptibilities differ among these four bacteria.
P. anaerobius, P. asaccharolyticus and F. magna are
resistant to some b-lactams. P. anaerobius tends to show
resistance more frequently than the others. Resistance to
macrolides and certain ﬂuoroquinolones is more common
with P. asaccharolyticus and F. magna than with the
others. Furthermore, P. micra shows resistance to various
drugs although not at a high frequency.
Atopobium vaginae
Atopobium vaginae is another bacterium, in addition to
those listed above, for which knowledge regarding drug
resistance would be desirable. This is a recently discovered
anaerobic gram-positive rod (described as a ‘‘coccus’’ in
some reports), suggested as one of the pathogens for bac-
terial vaginosis. This bacterium does not require strictly
anaerobic environments for its growth and is hence resis-
tant to metronidazole [4].
J Infect Chemother (2011) 17 (Suppl 1):162–164 163
123
References
1. Nakatsuji T. Exploration of b-lactamase gene in Prevotella using
PCR––based on analysis of carpenemase gene derived from
Prevotella nigrescens TO167. Jpn J Chemother. 2002;50:16–24.
(Japanese).
2. Wexler HM, Reeves D, Summanen PH, Molitoris E, McTeague M,
Duncan J, et al. Sutterella wadsworthensis gen. nov., sp. Nov.,
bile-resistant microaerophilic Campylobacter gracilis-like clinical
isolates. Int J Syst Bacteriol. 1996;46:252–8.
3. Lozniewski A, Labia R, Haristoy X, Mory F. Antimicrobial
susceptibilities of clinical Desulfovibrio isolates. Antimicrob
Agents Chemother. 2001;45:2933–5.
4. Ferris MJ, Masztal A, Aldridge KE, Fortenberry JD, Fidel PL Jr.,
Martin DH. Association of Atopobium vaginae, a recently
described metronidazole resistant anaerobe, with bacterial vagin-
osis. BMC Infect Dis 2004;4:5. Available from: http://www.
biomedcentral.com/1471-2334/4/5.
164 J Infect Chemother (2011) 17 (Suppl 1):162–164
123
